NL-OMON20976招募中不适用
Pragmatic trial baricitinib versus First biological in ''Tight Control'' Patients suffering from Rheumatoid Arthritis
prof. dr. M.A.F.J. van de Laar0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Clinical diagnosis of RA
- •Active disease (for example DAS28> 3.2 )
- •Former treatment according to T2T principles, at the discretion of the attending rheumatologist, i.e. past treatment decisions informed by disease activity measurements
- •Previous use of at least one csDMARD
排除标准
- •Disease duration >5 years
- •Previous treatment with any biological DMARD or tsDMARD
- •Contraindication for either TNFi or baricitinib
- •Latent or active tuberculosis
- •Active or recurrent infections
- •3x upper limit of normal ALAT
- •GFR < 30 ml/min.
- •Failure to provide written informed consent
- •Refusal to use effective contraceptive during the study period
研究者
相似试验
进行中（未招募）
1 期
Baricitinib in patients suffering from Rheumatoid ArthritisPragmatic trial baricitinib versus First biological in Tight Control” Patients suffering from Rheumatoid Arthritis (PERFECT)EUCTR2019-000505-72-NLTransparency in Healthcare200
已完成
4 期
Pragmatic trial baricitinib versus First biological in *Tight Control* Patients suffering from Rheumatoid Arthritis (PERFECT)NL-OMON48248Overige Centra200
尚未招募
3 期
studing the therapeutic effect of baricitinib and its side effects in LPP (Lichen Plano Pilaris)lichen planopilaris.Chapter XII Diseases of the skin and subcutaneous tissue(L00-L99)IRCT20221101056374N1Tehran University of Medical Sciences22
进行中（未招募）
2 期
Phase II proof of concept study of baricitinib in individuals who are considered at risk of developing inflammatory arthritis: ExISTInflammatory arthritisMusculoskeletal DiseasesISRCTN53678960niversity of Leeds58
招募中
3 期
Evaluation of therapeutic effect of baricitinib in patients with severe pneumonia requiring non-invasive ventilation induced to Covid 19Acute viral infection caused by the corona virus (COVID-19).COVID-19, virus identifiedU07.1IRCT20220508054780N1Mashhad University of Medical Sciences15